Jaclyn M. Jaskowiak, PharmD, BCPS, BCSCP

home / authors / jaclyn-m-jaskowiak-pharmd-bcps-bcscp

Articles

Hospital Pharmacy | Image Credit: Diego Cervo - stock.adobe.com

Implementing a Longitudinal Sterile Compounding Rotation for Pharmacy Residents

Jaclyn M. Jaskowiak, PharmD, BCPS, BCSCP
July 17th 2024

This manuscript will describe the creation and development of a longitudinal sterile compounding rotation at an academic medical center for postgraduate year 1 acute care pharmacy residents.

Read More

Credit: tyyang - stock.adobe.com

A Training Program Addresses Challenges in USP <797> Personnel Competency Evaluations at a Multisite Institution

Stephanie Truong, PharmD, BCPS;Jaclyn M. Jaskowiak, PharmD, BCPS, BCSCP;Sam Martinez, PharmD, BCOP, BCPS;Han Dinh, PharmD, BCPS;Mitchell Vitale, PharmD
September 21st 2023

Implementing these standards can be logistically challenging.

Read More

Latest Updated Articles

AI patient pharmacist provider interactions ASHP summer
Published: June 11th 2024 | Updated: July 27th 2024
Balancing Trust and Technology: The Role of AI in Patient-Pharmacist Interactions
AI pharmacy futures AI disparities skin
Published: June 11th 2024 | Updated: July 27th 2024
Addressing Disparities in AI-Driven Diagnostics: Ethical and Practical Implications
Vice President Kamala Harris -- Image credit: Erin Schaff/Pool/AFP | GETTY | People.com
Published: July 23rd 2024 | Updated: July 27th 2024
VP Kamala Harris’s Policies and Stances on Health Care, Reproductive Rights Take Center Stage
3d illustration of Abstract medical background with Diseased liver - Image credit: Rasi | stock.adobe.com
Published: October 18th 2023 | Updated: July 27th 2024
Pharmacists Can Optimize Treatment for Patients with NASH, Decreasing Economic Burden
Small vial of influenza vaccine.
Published: July 23rd 2024 | Updated: July 27th 2024
Trivalent Influenza Vaccines Are Readied for Fall
Eye Care Pharmacy | Image Credit: I Viewfinder - stock.adobe.com
Published: July 15th 2024 | Updated: July 27th 2024
Biosimilar Ranibizumab Could be More Cost-Effective Than Aflibercept for nAMD